Okuno, Scott

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology

Sarcoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 1,452

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma

Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., et al. (2019) · Journal of Clinical Oncology

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 268

Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

Keung, E. Z., Burgess, M., Salazar, R., Parra, E. R., Rodrigues-Canales, J., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Attia, S., Riedel, R. F., et al. (2020) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersSarcoma Diagnosis and Treatment

Cited by 215

Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

Chawla, S. P., Cranmer, L. D., Van Tine, B. A., Reed, D. R., Okuno, S. H., Butrynski, J. E., Adkins, D. R., Hendifar, A. E., Kroll, S., & Ganjoo, K. N. (2014) · Journal of Clinical Oncology

Sarcoma Diagnosis and TreatmentBioactive Compounds and Antitumor Agents

Cited by 155

Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas

Schulte, B., Mohindra, N., Milhem, M., Attia, S., Robinson, S., Monga, V., Hirbe, A. C., Oppelt, P., Charlson, J., Helenowski, I., et al. (2021) · British Journal of Cancer

Sarcoma Diagnosis and TreatmentCancer therapeutics and mechanisms

Cited by 19